Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma.
BACKGROUND
Treatment strategies targeting angiogenesis have revealed promising results in preclinical studies and early clinical trials in patients with glioblastomas.


OBJECTIVE
This review evaluates the preclinical and clinical data for cediranib (AZD2171), a potent oral inhibitor of the VEGF receptor tyrosine kinase.


METHODS
We summarize both preclinical and clinical data for cediranib, with a focus on the treatment of glioblastomas.


CONCLUSIONS
Cediranib is an effective drug in patients with glioblastoma, acting through inhibition of angiogenesis and normalization of tumor vasculature. Reduction of vasogenic brain edema is a key component of its treatment effect in this patient population. The primary side effects of cediranib include fatigue, diarrhea and hypertension.
Dietrich
Jörg
J
Stephen E and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.
Wang
Daphne
D
Batchelor
Tracy T
TT
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D005909:Glioblastoma / Q000098:blood supply / Q000188:drug therapy*; D006801:Humans; D011799:Quinazolines / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D007211:Indoles
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D011799:Quinazolines; D040262:Receptors, Vascular Endothelial Growth Factor; C500926:cediranib; D007211:Indoles